Reports
Reports
Analyst Viewpoint
The global gene delivery system industry size is driven by rise in incidence of genetic disorders and advancements in gene therapy research. Stakeholders in the market are developing safer and more efficient viral vectors for gene delivery. Targeted and low-dose frequency drug delivery systems are also gaining traction in the gene delivery system market statistics.
Increase in investment in biotechnology and pharmaceutical research is likely to offer lucrative opportunities to vendors in the global gene delivery system industry. However, high cost of gene therapy and surge in drug recalls due to stringent regulations in developed countries are estimated to limit the gene delivery system market growth in the near future.
Gene delivery is a procedure that introduces foreign DNA into host cells. Gene delivery systems are used to deliver therapeutic drugs targeting a specific area. Gene therapy administers an appropriate material to replace a defective or missing gene.
It is primarily employed in the treatment of inherited genetic disorders. Gene therapy is also used in the treatment of other diseases such as autosomal or X-linked recessive single-gene disorders, sickle cell anemia, phenylketonuria, hemophilia, and Duchenne muscular dystrophy.
Viral gene delivery, non-viral gene delivery, and combined hybrid are various types of gene delivery systems. Viral gene delivery systems include viral gene delivery, adenovirus vector, lentivirus vector, retrovirus vector, adeno-associated virus vector, sendai virus vector, and herpes simplex virus vector.
Natural organic compounds, physical methods, and chemical methods are major types of non-viral gene delivery systems. Viral vectors are one of the most successful genetic material transport systems. These vectors include retrovirus, adenovirus (types 2 and 5), adeno-associated virus, herpes virus, pox virus, human foamy virus (HFV), and lentivirus.
Gene delivery systems are essentially necessary for the gene therapy of human genetic diseases. Genetic diseases seriously threaten human health. siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA, miRNA, and other gene therapy drugs have shown great potential in the treatment of various diseases, including viral infections, certain cancers, and genetic disorders. Thus, high prevalence of genetic disorders is boosting the gene delivery system market demand. According to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 infants are born with sickle cell disease per year globally, and nearly 5% of the world's population is affected by the disease.
Development of new generations of precise vectors with sustainable effects is expected to augment the gene delivery system market progress in the near future. Limitations of existing vectors have prompted the use of modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have the potential to expand future applications for gene therapy.
HSV has many features that make it a potentially attractive vehicle for gene transfer most particularly to neurons.
Recent developments in drug delivery systems are primarily focused on smart drug delivery. Safe, efficient, and specific delivery of therapeutic genes plays a major role in the development of gene therapy. Synthetic vector systems are gaining traction in this regard due to their safety, lack of immunogenicity, very low frequency of integration, and relative ease of large-scale production.
Moreover, conventional drug delivery systems offer various disadvantages such as poor bioavailability and fluctuations in plasma drug levels. Thus, targeted and low-dose frequency drug delivery systems are gaining popularity in the treatment of various diseases. This, in turn, is fueling the gene delivery system market value.
According to the latest gene delivery system market trends, the viral gene delivery system segment held largest share in 2022. Increase in demand for viral gene delivery systems for the treatment of genetic and acquired diseases is driving the segment.
Lentiviral vector is one of the preferred tools for ex vivo transgene delivery for gene therapy. Lentiviruses, unlike some other viral vectors, can transduce both dividing and non-dividing cells. Thus, they are ideal vehicles to investigate combinatorial gene transfer into diverse cells.
According to the latest gene delivery system market forecast, the oncology application segment is expected to account for major share from 2023 to 2031. Growth of the segment can be ascribed to the rise in the incidence of cancer across all regions. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths were projected to occur in the U.S., according to the National Center for Health Statistics.
According to the latest gene delivery system market research, the injectable route of administration segment held largest share in 2022. The injectable route of administration is used for rapid drug absorption. Especially, drugs with low oral bioavailability are administered through the intramuscular or subcutaneous route. Oral formulations are inexpensive as compared to other dosage forms. This route of drug administration allows sustained release of formulation to reduce the frequency of the medication.
North America accounted for major gene delivery system market share in 2022. Rise in prevalence of genetic disorders and technological advancements in drug delivery systems are driving the market dynamics of the region. The prevalence of children aged 0 to 17 years with a reported genetic condition in the U.S. was approximately 0.039, roughly equating to 2.8 million children in 2016-2017, according to a 2022 study published in the journal Genetics in Medicine.
Gene delivery system manufacturers are harnessing the power of biotechnology, chemistry, and genetic medicine to offer products that redefine the treatment of various disorders. Gene therapy is generally expensive as their development involves extensive research and development efforts. Thus, vendors are investing in innovative clinical trials to offer medicines that are accessible and affordable.
Safety is a major concern in gene therapy. There have been several product recalls in the recent past. In November 2023, Bayer voluntarily recalled a single lot of its cancer therapy Vitrakvi (larotrectinib) oral solution 20mg/mL, available in 100mL glass bottles.
Vitrakvi treats NTRK gene fusion-positive solid tumors. Patients receiving the drug may therefore already be immunocompromised. Hence, gene delivery system companies are focusing on careful product design, rigorous testing, and ongoing monitoring to enhance safety in gene therapy. They are also adopting in vivo imaging techniques for monitoring gene delivery system efficacy.
Major players operating in the market include Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono GeneTech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., and Human Stem Cells Institute.
The gene delivery system market report highlights these companies in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 5.4 Bn |
| Market Forecast Value in 2031 | US$ 10.0 Bn |
| Growth Rate (CAGR) | 7.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 5.4 Bn in 2022
It is projected to grow at a CAGR of 7.2% from 2023 to 2031
Rise in incidence of genetic disorders and advancements in gene therapy research
The viral gene delivery system was the largest delivery system segment in 2022
North America was the most lucrative region in 2022
Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono GeneTech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., and Human Stem Cells Institute
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Delivery System Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Delivery System Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Delivery System Market Analysis and Forecast, by Delivery System
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Delivery System, 2017–2031
6.3.1. Viral Gene Delivery
6.3.1.1. Adenovirus Vector
6.3.1.2. Lentivirus Vector
6.3.1.3. Retrovirus Vector
6.3.1.4. Adeno-associated Virus Vector
6.3.1.5. Sendai Virus Vector
6.3.1.6. Herpes Simplex Virus Vector
6.3.1.7. Others
6.3.2. Non-viral Gene Delivery
6.3.2.1. Natural Organic Compounds
6.3.2.2. Physical Methods
6.3.2.3. Chemical Methods
6.3.3. Combined Hybrid Delivery
6.4. Market Attractiveness Analysis, by Delivery System
7. Global Gene Delivery System Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Infectious Diseases
7.3.2. Oncology
7.3.3. Ophthalmology
7.3.4. Urology
7.3.5. Diabetes
7.3.6. CNS
7.3.7. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Gene Delivery System Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Inhalation
8.3.4. Transdermal
8.3.5. Ocular
8.3.6. Nasal
8.3.7. Topical
8.4. Market Attractiveness Analysis, by Application
9. Global Gene Delivery System Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gene Delivery System Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Delivery System, 2017–2031
10.3.1. Viral Gene Delivery
10.3.1.1. Adenovirus Vector
10.3.1.2. Lentivirus Vector
10.3.1.3. Retrovirus Vector
10.3.1.4. Adeno-associated Virus Vector
10.3.1.5. Sendai Virus Vector
10.3.1.6. Herpes Simplex Virus Vector
10.3.1.7. Others
10.3.2. Non-viral Gene Delivery
10.3.2.1. Natural Organic Compounds
10.3.2.2. Physical Methods
10.3.2.3. Chemical Methods
10.3.2.4. Acute Dialysis Products
10.3.3. Combined Hybrid Delivery
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Infectious Diseases
10.4.2. Oncology
10.4.3. Ophthalmology
10.4.4. Urology
10.4.5. Diabetes
10.4.6. CNS
10.4.7. Others
10.5. Market Value Forecast, by Route of Administration, 2017–2031
10.5.1. Oral
10.5.2. Injectable
10.5.3. Inhalation
10.5.4. Transdermal
10.5.5. Ocular
10.5.6. Nasal
10.5.7. Topical
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Delivery System
10.7.2. By Application
10.7.3. By Route of Administration
10.7.4. By Country
11. Europe Gene Delivery System Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Delivery System, 2017–2031
11.3.1. Viral Gene Delivery
11.3.1.1. Adenovirus Vector
11.3.1.2. Lentivirus Vector
11.3.1.3. Retrovirus Vector
11.3.1.4. Adeno-associated Virus Vector
11.3.1.5. Sendai Virus Vector
11.3.1.6. Herpes Simplex Virus Vector
11.3.1.7. Others
11.3.2. Non-viral Gene Delivery
11.3.2.1. Natural Organic Compounds
11.3.2.2. Physical Methods
11.3.2.3. Chemical Methods
11.3.2.4. Acute Dialysis Products
11.3.3. Combined Hybrid Delivery
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Infectious Diseases
11.4.2. Oncology
11.4.3. Ophthalmology
11.4.4. Urology
11.4.5. Diabetes
11.4.6. CNS
11.4.7. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Oral
11.5.2. Injectable
11.5.3. Inhalation
11.5.4. Transdermal
11.5.5. Ocular
11.5.6. Nasal
11.5.7. Topical
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Delivery System
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Country/Sub-region
12. Asia Pacific Gene Delivery System Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Delivery System, 2017–2031
12.3.1. Viral Gene Delivery
12.3.1.1. Adenovirus Vector
12.3.1.2. Lentivirus Vector
12.3.1.3. Retrovirus Vector
12.3.1.4. Adeno-associated Virus Vector
12.3.1.5. Sendai Virus Vector
12.3.1.6. Herpes Simplex Virus Vector
12.3.1.7. Others
12.3.2. Non-viral Gene Delivery
12.3.2.1. Natural Organic Compounds
12.3.2.2. Physical Methods
12.3.2.3. Chemical Methods
12.3.2.4. Acute Dialysis Products
12.3.3. Combined Hybrid Delivery
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Infectious Diseases
12.4.2. Oncology
12.4.3. Ophthalmology
12.4.4. Urology
12.4.5. Diabetes
12.4.6. CNS
12.4.7. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Inhalation
12.5.4. Transdermal
12.5.5. Ocular
12.5.6. Nasal
12.5.7. Topical
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Delivery System
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Country/Sub-region
13. Latin America Gene Delivery System Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Delivery System, 2017–2031
13.3.1. Viral Gene Delivery
13.3.1.1. Adenovirus Vector
13.3.1.2. Lentivirus Vector
13.3.1.3. Retrovirus Vector
13.3.1.4. Adeno-associated Virus Vector
13.3.1.5. Sendai Virus Vector
13.3.1.6. Herpes Simplex Virus Vector
13.3.1.7. Others
13.3.2. Non-viral Gene Delivery
13.3.2.1. Natural Organic Compounds
13.3.2.2. Physical Methods
13.3.2.3. Chemical Methods
13.3.2.4. Acute Dialysis Products
13.3.3. Combined Hybrid Delivery
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Infectious Diseases
13.4.2. Oncology
13.4.3. Ophthalmology
13.4.4. Urology
13.4.5. Diabetes
13.4.6. CNS
13.4.7. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Inhalation
13.5.4. Transdermal
13.5.5. Ocular
13.5.6. Nasal
13.5.7. Topical
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Delivery System
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Country/Sub-region
14. Middle East & Africa Gene Delivery System Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Delivery System, 2017–2031
14.3.1. Viral Gene Delivery
14.3.1.1. Adenovirus Vector
14.3.1.2. Lentivirus Vector
14.3.1.3. Retrovirus Vector
14.3.1.4. Adeno-associated Virus Vector
14.3.1.5. Sendai Virus Vector
14.3.1.6. Herpes Simplex Virus Vector
14.3.1.7. Others
14.3.2. Non-viral Gene Delivery
14.3.2.1. Natural Organic Compounds
14.3.2.2. Physical Methods
14.3.2.3. Chemical Methods
14.3.2.4. Acute Dialysis Products
14.3.3. Combined Hybrid Delivery
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Infectious Diseases
14.4.2. Oncology
14.4.3. Ophthalmology
14.4.4. Urology
14.4.5. Diabetes
14.4.6. CNS
14.4.7. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Inhalation
14.5.4. Transdermal
14.5.5. Ocular
14.5.6. Nasal
14.5.7. Topical
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Delivery System
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Oxford Biomedica PLC
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sibiono GeneTech Co., Ltd.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Shanghai Sunway Biotech Co., Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Bayer AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Johnson & Johnson Services, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Human Stem Cells Institute
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 02: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 07: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 11: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 13: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 15: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 19: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 23: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
List of Figures
Figure 01: Global Gene Delivery System Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Gene Delivery System Market Revenue (US$ Mn), by Delivery System, 2022
Figure 03: Global Gene Delivery System Market Value Share, by Delivery System, 2022
Figure 04: Global Gene Delivery System Market Revenue (US$ Mn), by Application, 2022
Figure 05: Global Gene Delivery System Market Value Share, by Application, 2022
Figure 06: Global Gene Delivery System Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 07: Global Gene Delivery System Market Value Share, by Route of Administration, 2022
Figure 08: Global Gene Delivery System Market Value Share, by Region, 2022
Figure 09: Global Gene Delivery System Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 11: Global Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 12: Global Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 13: Global Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 14: Global Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 15: Global Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 16: Global Gene Delivery System Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Gene Delivery System Market Attractiveness Analysis, by Region, 2023–2031
Figure 18: North America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Gene Delivery System Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Gene Delivery System Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 22: North America Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 23: North America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 24: North America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 25: North America Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 26: North America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 27: Europe Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 31: Europe Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 32: Europe Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 33: Europe Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 34: Europe Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 35: Europe Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 36: Asia Pacific Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 40: Asia Pacific Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 41: Asia Pacific Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 42: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 43: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 44: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 45: Latin America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 49: Latin America Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 50: Latin America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 51: Latin America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 52: Latin America Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 53: Latin America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 54: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031
Figure 58: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Application, 2022–2031
Figure 59: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 60: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 61: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031
Figure 62: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gene Delivery System Market